Piper Sandler Reiterates Overweight on Health Catalyst, Raises Price Target to $12

Benzinga · 11/26 13:04
Piper Sandler analyst Jessica Tassan reiterates Health Catalyst (NASDAQ:HCAT) with a Overweight and raises the price target from $11 to $12.